Mark Bhatt

Mark Bhatt investigates thiopurine pharmacogenomics with particular focus on how TPMT and NUDT15 genetic variants affect the metabolism and toxicity of mercaptopurine and thioguanine in childhood leukemia. His research has clarified why NUDT15 variants confer profound thiopurine toxicity in Asian populations, informing dosing guidelines globally. He has developed pre-treatment pharmacogenomic screening programs that reduce severe hematologic toxicity while maintaining therapeutic efficacy. His work exemplifies how pediatric oncology has led implementation of pharmacogenomics into standard care.